uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.124.268278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Edwin C Pratt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Receptors, Urokinase Plasminogen Activator, Positron-Emission Tomography. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Identifying cancer therapy resistance is a key time-saving tool for physicians. Part of chemotherapy resistance includes senescence, a persistent state without cell division or cell death. Chemically inducing senescence with the combination of trametinib and palbociclib (TP) yields several tumorigenic and prometastatic factors in pancreatic cancer models with many potential antibody-based targets. In particular, urokinase plasminogen activator receptor (uPAR) has been shown to be a membrane-bound marker of senescence in addition to an oncology target.
Methods
Here, 2 antibodies against murine uPAR and human uPAR were developed as immuno-PET agents to noninvasively track uPAR antigen abundance.
Results
TP treatment increased cell uptake both in murine KPC cells and in human MiaPaCa2 cells. In vivo, subcutaneously implanted murine KPC tumors had high tumor uptake with the antimurine uPAR antibody independently of TP in young mice, yet uPAR uptake was maintained in aged mice on TP. Mice xenografted with human MiaPaCa2 tumors showed a significant increase in tumor uptake on TP therapy when imaged with the antihuman uPAR antibody. Imaging with either uPAR antibody was found to be more tumor-selective than imaging with [18F]FDG or [18F]F-DPA-714.
Conclusion
The use of radiolabeled uPAR-targeting antibodies provides a new antibody-based PET imaging candidate for pancreatic cancer imaging as well as chemotherapy-induced senescence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York.
- Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
- HHMI, Memorial Sloan Kettering Cancer Center, New York, New York; and.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; Lewisj2@mskcc.org.
- Department of Pharmacology, Weill Cornell Graduate School, New York, New York.
Förderung
- NIH HHS
- NCI NIH HHS
Zitieren
APA
Pratt, E. C., Mezzadra, R., Kulick, A., Kaminsky, S., Samuels, Z. V., Loor, A., de Stanchina, E., Lowe, S. W., & Lewis, J. S. (2024). uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268278
Vancouver
Pratt EC, Mezzadra R, Kulick A, Kaminsky S, Samuels ZV, Loor A, et al. uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.124.268278
BibTeX
@article{Pratt2024,
author = {Pratt, Edwin C and Mezzadra, Riccardo and Kulick, Amanda and Kaminsky, Spencer and Samuels, Zachary V and Loor, Angelique and de Stanchina, Elisa and Lowe, Scott W and Lewis, Jason S},
title = {uPAR Immuno-PET in Pancreatic Cancer, Aging, and Chemotherapy-Induced Senescence},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.124.268278}
}
EUVIMED